ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,441 to 2,460 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
M-M-R II ® vs Placebo: Severity of COVID-19 Measured at 60 Days After Intervention3 of 1,607

1 of 1,544

0.1 points

-0.2 to 0.5

3,151NCT04333732

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

Rotarix Group vs Placebo Group: Number of Subjects With Any Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild-type Strains70 of 1,575

167 of 1,573

-6.2 points

-8.0 to -4.3

3,148NCT01171963

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Rotarix Group vs Placebo Group: Number of Subjects With Episodes of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild Type (WT) Strains Requiring Hospitalization4 of 1,575

21 of 1,573

-1.1 points

-1.8 to -0.5

3,148NCT01171963

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Rotarix Group vs Placebo Group: Number of Subjects With Severe Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild Type (WT) Strains21 of 1,575

75 of 1,573

-3.4 points

-4.7 to -2.3

3,148NCT01171963

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Lapatinib 1500 mg vs Placebo: Number of Participants With CNS Recurrence15 of 1,571

21 of 1,576

-0.4 points

-1.2 to 0.4

3,147NCT00374322

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Lapatinib 1500 mg vs Placebo: Number of Participants With Any Recurrence of the Initial Disease, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])184 of 1,571

231 of 1,576

-2.9 points

-5.3 to -0.6

3,147NCT00374322

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Lapatinib 1500 mg vs Placebo: serious adverse events99 of 1,573

78 of 1,574

1.3 points

-0.3 to 3.0

3,147NCT00374322

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Any Repeat Revascularization202 of 2,372

76 of 769

-1.4 points

-3.9 to 0.9

3,141NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Rate of Stent Thrombosis27 of 2,364

16 of 771

-0.9 points

-2.3 to 0.0

3,135NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Ischemia-driven Target Vessel Revascularization133 of 2,366

41 of 766

0.3 points

-1.8 to 2.0

3,132NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Ischemia-driven Target Lesion Revascularization117 of 2,364

38 of 766

-0.0 points

-2.0 to 1.6

3,130NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

M-M-R II ® vs Placebo: Number of Participants With Symptomatic COVID-19 at 150 Days65 of 1,585

64 of 1,544

-0.0 points

-1.5 to 1.4

3,129NCT04333732

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

M-M-R II ® vs Placebo: Severity of COVID-19 at 150 Days After Intervention3 of 1,585

1 of 1,544

0.1 points

-0.2 to 0.5

3,129NCT04333732

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

Enhanced Treatment vs Current Practice: serious adverse events6 of 1,017

15 of 2,108

-0.1 points

-0.7 to 0.6

3,125NCT00513500

Zambia Integrated Management of Malaria and Pneumonia Study

Bone Health Service Arm vs Usual Care (Control) Arm: Proportion With Fractures31 of 1,688

29 of 1,424

-0.2 points

-1.2 to 0.8

3,112NCT04079868

Models of Primary Osteoporosis Screening in Male Veterans

Bone Health Service Arm vs Usual Care (Control) Arm: Proportion of Participants Screened for Osteoporosis830 of 1,688

33 of 1,424

46.9 points

44.3 to 49.3

3,112NCT04079868

Models of Primary Osteoporosis Screening in Male Veterans

Bone Health Service Arm vs Usual Care (Control) Arm: Gastrointestinal Medication Prescriptions562 of 1,688

473 of 1,424

0.1 points

-3.2 to 3.4

3,112NCT04079868

Models of Primary Osteoporosis Screening in Male Veterans

Bone Health Service Arm vs Usual Care (Control) Arm: deaths from any cause135 of 1,688

89 of 1,424

1.7 points

-0.1 to 3.5

3,112NCT04079868

Models of Primary Osteoporosis Screening in Male Veterans

Pre-intervention vs Post-intervention: serious adverse events165 of 1,574

95 of 1,532

4.3 points

2.3 to 6.2

3,106NCT02320175

Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience

FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: deaths from any cause8 of 1,545

8 of 1,547

0.0 points

-0.6 to 0.6

3,092NCT03467425

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=123"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=123

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04333732-7d39caf8",
        "title": "M-M-R II ® vs Placebo: Severity of COVID-19 Measured at 60 Days After Intervention",
        "summary": "3 of 1607 against 1 of 1544; risk difference 0.1 points, 95% interval -0.2 to 0.5; NCT04333732, CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION",
        "record": "/library/comparisons/NCT04333732-7d39caf8",
        "nct_id": "NCT04333732",
        "kind": "outcome",
        "participants": 3151,
        "risk_difference": {
          "value": 0.0012191642135604914,
          "lower": -0.0020348982631645607,
          "upper": 0.004865965109806117
        },
        "group_1": "3 of 1,607",
        "group_2": "1 of 1,544",
        "difference": "0.1 points",
        "interval": "-0.2 to 0.5",
        "trial_title": "CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION"
      },
      {
        "id": "NCT01171963-36865e1e",
        "title": "Rotarix Group vs Placebo Group: Number of Subjects With Any Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild-type Strains",
        "summary": "70 of 1575 against 167 of 1573; risk difference -6.2 points, 95% interval -8.0 to -4.3; NCT01171963, Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants",
        "record": "/library/comparisons/NCT01171963-36865e1e",
        "nct_id": "NCT01171963",
        "kind": "outcome",
        "participants": 3148,
        "risk_difference": {
          "value": -0.06172211626757081,
          "lower": -0.08030643024848949,
          "upper": -0.04349454700825449
        },
        "group_1": "70 of 1,575",
        "group_2": "167 of 1,573",
        "difference": "-6.2 points",
        "interval": "-8.0 to -4.3",
        "trial_title": "Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=124",
  "request_id": "pSwDq8wc103iLi2P"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?